Revvity, Inc. (RVTY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Revvity, Inc. (RVTY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Fiscal Year: January - December
Revvity, Inc. (RVTY), listed on the NYSE, has a market capitalization of $9.94B. As of Apr 05, 2026, the stock is trading at $88.94 per share@else an unavailable price , offering investors a clear view of its current market value. Revvity, Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 43.21, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Revvity, Inc. also offers a dividend yield of 0.31%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Revvity, Inc. (RVTY) may be overvalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Revvity, Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Revvity, Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Revvity, Inc. is 19.52, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Revvity, Inc. (RVTY) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Revvity, Inc. (RVTY) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be overvalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Revvity, Inc. (RVTY) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Revvity, Inc.. To access the full SS Score, consider upgrading your subscription.
Revvity, Inc. is a significant player in the industry sector, with a market capitalization of $9.94B and a competitive P/E ratio of 43.21. Investors should compare these metrics with industry peers to gauge whether Revvity, Inc. is outperforming or underperforming within its sector.
Revvity, Inc. (RVTY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Revvity, Inc. (RVTY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Revvity, Inc. (RVTY) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Raymond James 47th Annual Institutional Investors Conference Monday,...
WALTHAM, Mass.--(BUSINESS WIRE)-- #LifeSciences--Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high...
Diagnostics is driving Revvity, Inc. growth, especially outside China. Signals software a standout: high-teens growth, SaaS ARR +40%. China immunodiagnostics and NIH funding remain key drags.
Revvity Inc. (NYSE: RVTY) on Monday reported better-than-expected earnings for the fourth quarter.
Revvity, Inc. (RVTY) Q4 2025 Earnings Call Transcript
Revvity Inc. (NYSE: RVTY) on Monday reported fourth quarter 2025 adjusted earnings of $1.70 per share, up 19.7% year over year, beating the consensus of $1.55.
Medical equipment maker Revvity handily beat fourth-quarter estimates and forecast 2026 revenue and profit above Wall Street expectations on Monday, betting on continued strength in its diagnostics bu...
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP...
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8...
Online travel agency Expedia, our top overall contributor in Q4, drove performance in the consumer discretionary sector. Our top performers in the energy and financials sectors were NOV, a provider of...
Revvity, Inc. (RVTY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Wall Street is split on the stock, and the shares are close to the average price target. Something's got to give.
Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and dia...
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2025 financial results prior to market open on Monday, February 2, 20...
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly's high-quality predictive models by making L...
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 44th annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:45 a.m. PT. President and Chief Executiv...
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the introduction of its forthcoming Signals Xynthetica™ Models-as-a Service (MaaS) AI offering within the Revvity Signals pl...
Revvity, Inc. (RVTY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Revvity, Inc. ( RVTY) Jefferies London Healthcare Conference 2025 November 18, 2025 9:00 AM EST Company Participants Maxwell Krakowiak - Senior VP & CFO Prahlad Singh - CEO, President & Director Conf...
Revvity, Inc. ( RVTY) UBS Global Healthcare Conference 2025 November 10, 2025 8:00 AM EST Company Participants Maxwell Krakowiak - Senior VP & CFO Conference Call Participants Daniel Leonard - UBS In...
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., today announced the launch of new highly-characterized somatic cancer reference standards developed in collaboration with the Medical Device Innovation ...
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that sup...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 595.98M | 10.03% | Est @10.0% |
| 2026 | 650.30M | 9.12% | Analyst x2 |
| 2027 | 687.60M | 5.74% | Analyst x2 |
| 2028 | 749.00M | 8.93% | Analyst x1 |
| 2029 | 813.00M | 8.54% | Analyst x1 |
| 2030 | 851.41M | 4.73% | Est @4.7% |
| 2031 | 886.15M | 4.08% | Est @4.1% |
| 2032 | 918.25M | 3.62% | Est @3.6% |
| 2033 | 948.56M | 3.30% | Est @3.3% |
| 2034 | 975.78M | 2.87% | Est @2.9% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 9.90M | 1.00 | 9.90M |
| 2024A | 541.65M | 1.00 | 541.65M |
| 2025E | 595.98M | 1.09 | 548.77M |
| 2026E | 650.30M | 1.18 | 551.36M |
| 2027E | 687.60M | 1.28 | 536.81M |
| 2028E | 749.00M | 1.39 | 538.43M |
| 2029E | 813.00M | 1.51 | 538.14M |
| 2030E | 851.41M | 1.64 | 518.93M |
| 2031E | 886.15M | 1.78 | 497.32M |
| 2032E | 918.25M | 1.94 | 474.52M |
| 2033E | 948.56M | 2.10 | 451.35M |
| 2034E | 975.78M | 2.28 | 427.52M |
| Terminal | 16.39B | 2.28 | 7.18B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.